RT Journal Article
T1 Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival.
A1 Loucera, Carlos
A1 Perez-Florido, Javier
A1 Casimiro-Soriguer, Carlos S
A1 Ortuño, Francisco M
A1 Carmona, Rosario
A1 Bostelmann, Gerrit
A1 Martinez-Gonzalez, L Javier
A1 Muñoyerro-Muñiz, Dolores
A1 Villegas, Roman
A1 Rodriguez-Baño, Jesus
A1 Romero-Gomez, Manuel
A1 Lorusso, Nicola
A1 Garcia-Leon, Javier
A1 Navarro-Mari, Jose M
A1 Camacho-Martinez, Pedro
A1 Merino-Diaz, Laura
A1 Salazar, Adolfo de
A1 Viñuela, Laura
A1 Lepe, Jose A
A1 Garcia, Federico
A1 Dopazo, Joaquin
K1 COVID-19
K1 SARS-CoV-2
K1 phylogeny
K1 survival
K1 virus genome
AB More than two years into the COVID-19 pandemic, SARS-CoV-2 still remains a global public health problem. Successive waves of infection have produced new SARS-CoV-2 variants with new mutations for which the impact on COVID-19 severity and patient survival is uncertain. A total of 764 SARS-CoV-2 genomes, sequenced from COVID-19 patients, hospitalized from 19th February 2020 to 30 April 2021, along with their clinical data, were used for survival analysis. A significant association of B.1.1.7, the alpha lineage, with patient mortality (log hazard ratio (LHR) = 0.51, C.I. = [0.14,0.88]) was found upon adjustment by all the covariates known to affect COVID-19 prognosis. Moreover, survival analysis of mutations in the SARS-CoV-2 genome revealed 27 of them were significantly associated with higher mortality of patients. Most of these mutations were located in the genes coding for the S, ORF8, and N proteins. This study illustrates how a combination of genomic and clinical data can provide solid evidence for the impact of viral lineage on patient survival.
PB MDPI AG
YR 2022
FD 2022-08-27
LK http://hdl.handle.net/10668/21601
UL http://hdl.handle.net/10668/21601
LA en
NO Loucera C, Perez-Florido J, Casimiro-Soriguer CS, Ortuño FM, Carmona R, Bostelmann G, et al. Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival. Viruses. 2022 Aug 27;14(9):1893.
DS RISalud
RD Apr 7, 2025